Since the early 2000s, new immunotherapeutic agents that are utilized in the treatment of various diseases, particularly a wide array of monoclonal antibodies targeting TNFα and other cytokines [36] as well as lymphocyte antigens, have been further recognized as risk factors for PCP (Table 1). This evidence concerns the gene TNF and pneumocystosis.